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Cabergoline therapy for Macroprolactinoma
during pregnancy: A case report
Hira Shahzad1*, Aisha Sheikh2 and Lumaan Sheikh3
Abstract
Background: We assessed the safety of Cabergoline therapy during pregnancy in a lady with hyperprolactinemia
intolerant to Bromocriptine.
Case presentation: We report the case of a 31 year old lady who presented to us with uncontrolled
hyperprolactinemia. A pituitary Macroadenoma was demonstrated by MRI. Due to intolerance to Bromocriptine,
Cabergoline was started. The patient improved and subsequently conceived. MRI in the second trimester
demonstrated further reduction in the tumor size. It was decided to continue Cabergoline throughout pregnancy
to ensure further reduction in tumor size until delivery and to hold Cabergoline during postpartum period to allow
for an adequate interval of breastfeeding. At 37 weeks of gestation, the patient delivered a healthy baby.
Conclusion: We were able to safely treat macroprolactinemia in our patient during pregnancy with cabergoline.
This case report contributes to the relatively meager data available which advocates the safety of cabergoline
therapy in pregnant hyperprolactinemic patients.
Background
Prolactinomas are the most common hormone secreting
pituitary adenomas and comprise 40% of all pituitary
tumors [1,2]. Until the mid 1980s, surgery was the pre-
ferred treatment of choice in patients with macroprolac-
tinomas [2]. With the introduction of Bromocriptine
(BRC) in 1972 this trend changed [3]. Trials proved that
BRC lowered prolactin levels efficiently, improved symp-
toms and helped in reduction of the size of tumor itself.
Usually drugs are stopped once a patient becomes preg-
nant to limit fetal exposure. At this point in time, data
of over 6000 pregnancies with BRC evaluated in this
fashion is available [4]. Cabergoline (CAB) is another
drug belonging to the class of dopamine agonists that
was approved for use in 1985 which is usually preferred
over BRC due to its higher effectiveness in prolactin
suppression and tumor reduction [5]. It has been found
to be effective in patients who are refractory to BRC [6].
Moreover, its longer half life requires less frequent dos-
age, and a more feasible side effect profile have resulted
in increased compliance by patients [6]. However litera-
ture regarding the safety of CAB during pregnancy is
lacking [4]. Therefore CAB is not regarded as the first
line drug and is used only as an alternative when BRC
therapy fails [6]. We are reporting this case in order to
contribute to the relatively meager data available to ad-
vocate the safety of cabergoline therapy in pregnant
patients with hyperprolactinemia.
Case presentation
A 31 year old lady, mother of three children, presented
to the endocrinology clinic with an eight year history of
hyperprolactinemia. Her prolactin levels at that time
were found to be high, and according to the patient the
MRI was normal and showed no evidence of a pituitary
tumor. However these reports were not available to us
for verification. She admitted to having been non-
compliant with bromocriptine (BRC) 2.5 mg twice a day
as had been prescribed to her due to tolerance issues. It
is unclear as to how closely her prolactin (PRL) levels
had been monitored.
She had been taking BRC regularly for the last 3 months
along with progesterone injections for withdrawal bleeding.
PRL was 1300ng/dl (1.9 – 25 ng/ml). On physical examina-
tion, her body mass index (BMI) was 29 kg/m2. Visual
fields were full by confrontation. Breast examination
revealed expressible galactorrhea. There was evidence of
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acanthosis nigricans. Magnetic Resonance Imaging (MRI)
was advised which showed a Pituitary Macroadenoma
measuring 2.2 cm× 2 cm× 1.3 cm with minimal suprasel-
lar extension, involving the right cavernous sinus with en-
casement of internal carotid artery and extending into the
optic canal abutting the optic chiasm superiorly. (Figure 1)
Due to cost issues with cabergoline (CAB), she was given
another trial of BRC starting with a low dose with the
intention of raising it up to 2.5 mg thrice daily within a
month.
Since PRL levels remained high necessitating a dose
build up of BRC and the patient still complained of in-
tolerance to BRC, CAB was started at a low dose of 0.25
mg once a week. Due to persistently high PRL levels,
CAB was increased to 0.5mg twice weekly. Any efforts
to increase the dose further failed since the patient was
unable to tolerate it. PRL dropped to 40ng/dl after eight
months of CAB initiation. Her menstrual cycles returned
to normal. A repeat MRI demonstrated the pituitary
mass which had now decreased to 2.0 × 1.7 × 0.7 cm. Pa-
tient improved symptomatically as well as biochemically.
Twenty months after her initial presentation to us, the
patient conceived. Because of the fact that she had
macroprolactinoma, she was advised to continue CAB at
0.5mg once weekly. She was also given supplemental
folic acid 5 mg once daily and Meclizine for morning
sickness. A viable pregnancy was confirmed with ultra-
sound and patient was referred for antenatal care.
Fetal Nuchal thickness ultrasound performed at 13
weeks to screen for major chromosomal abnormalities
was normal. MRI was repeated in the second trimester
in order to assess the tumor size. MRI without contrast
demonstrated further reduction in the tumor size,
pituitary mass now being 1.8 × 1.0 cm. (Figure 2) It was
decided to continue CAB throughout pregnancy to en-
sure further reduction in tumor size until delivery and to
hold CAB during postpartum period to allow for an
adequate interval of breastfeeding. Perimetry was re-
peated every three months to check visual fields which
remained normal. At 25 weeks of pregnancy, patient
complained of headaches not effectively relieved with
analgesics and therefore CAB was reduced to 0.25 mg
weekly.
At 28 weeks of gestation, patient developed general-
ized pruritus and dark urine. Liver function tests (LFTs)
showed raised levels of ALT (SGPT) = 281 (< 34 IU/L),
AST (SGOT) = 220 (< 31 IU/L) and Alkaline Phosphatase=
211 (42–121). Total and direct bilirubin levels were
within the normal range. Ultrasound of liver and gall-
bladder was normal. Hepatitis profile was also normal.
Diagnosis of cholestatic jaundice was made (serum bile
acids are not available in our laboratory). Patient
received Urodeoxycholic acid 500 mg at thrice daily
dosage. CAB was continued at 0.25 mg weekly through-
out this time period.
At 37 + weeks of gestation labor was induced due to
obstetric cholestasis. She had an assisted vaginal delivery
due to abnormal fetal heart rate during the second stage
of labor. A live baby boy weighing 3 kg was delivered
with an Apgar score of 8 at 1 and 9 at 5 minutes. Her
postpartum period was uneventful. Serum ALT levels
checked after 10 days of delivery were normal. To allow
breast feeding her Cabergoline was stopped. Her Prolac-
tin level after 6 months of delivery while she was breast
feeding her baby and was off cabergoline was 61.4 ng/ml.
As she opted to continue breast feeding her baby further
Figure 1 MRI (T1 weighted image) showing a Pituitary
Macroadenoma measuring 2.2 cm × 2 cm × 1.3 cm (marked
with a red arrow), with minimal supra-sellar extension,
involving the right cavernous sinus with encasement of
internal carotid artery and extending into the optic canal
abutting the optic chiasm superiorly.
Figure 2 Repeat MRI (T1 weighted image) in the second
trimester during pregnancy was done in order to assess the
tumor size. It demonstrates considerable reduction in the tumor
size, pituitary mass now being 1.8 × 1.0 cm (marked with a red
arrow) as compared to the previous MRI shown in Figure 1.
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she was not advised to restart cabergoline. Her baby is
doing well one year postpartum. The patient continues to
remain amenorrheic since she delivered. Her follow up
with a repeat Prolactin level is awaited.
Discussion
BRC and CAB have been extensively compared in clin-
ical trials and studies with respect to their side-effect
profiles and the relative ease of achieving pregnancy in
hyperprolactinemic women [4,7]. One such study com-
pared BRC and CAB in two groups of patients with
hyperprolactinemia and reported that the frequency of
galactorrhea and irregular menstruation were found to
be lower in women receiving CAB and pregnancy was
more frequently achieved among these patients [7].
Once ovulation and fertility is reinstated in women
with hyperprolactinemia, there are two main issues dur-
ing the course of the pregnancy; firstly, the effects of
dopamine agonists on early fetal development and the
outcome of pregnancy, and secondly, the effect of hor-
monal milieu on the size of prolactinoma. Of the data
available for BRC from 6000 pregnancies studied, it was
found that there was no significant difference in the in-
cidence of spontaneous abortions, ectopic pregnancies,
trophoblastic diseases or multiple pregnancies and
only 1.8% had congenital malformations [4,8,9]. CAB
studies demonstrated similar results with a frequency
of 2.2% congenital malformations [10] which is still
lower than the incidence (3.0%) found in the general
population [11].
Tumor growth during pregnancy is another concern in
this population. Since a rise in estrogen levels induces
prolactin synthesis and secretion, it subsequently leads
on to lactotroph cell hyperplasia and an increase in
tumor size. Moreover, stopping dopamine agonistic ther-
apy during this time period in order to protect the fetus
from adverse effects associated with its continuation,
causes further growth in the size of prolactinoma. Keep-
ing this in mind, we ordered a repeat MRI for our pa-
tient during the second trimester in order to decide
whether to withhold CAB therapy during pregnancy. By
continuing therapy, we could diminish the size of tumor
further such that once she delivered the child, we could
hold CAB while she breastfed.
In their study [10], Lebbe et al. evaluated 100 pregnan-
cies for the risk of adverse outcomes in females previ-
ously diagnosed with hyperprolactinemia who were
being treated with CAB for a month or more before
conceiving. Even though all patients had been advised
to discontinue CAB as soon as their pregnancies were
confirmed, 13 continued with therapy for variable time
period. Cumulative fetal dose was calculated as the
product of dose of CAB at discontinuation and the
length of gestation during which CAB was given.
Spontaneous miscarriages occurred in 10% and three
medical terminations of pregnancy were performed for
fetal malformations (3%). The remaining 84 deliveries
resulted in 88 infants, three of whom presenting with a
malformation (3.4%). On comparison, a malformation
rate of 6.3% was found in the control group. Postnatal
development of the children was normal.
A study showed that 78% of the women who received
CAB therapy before and/or during early pregnancy
delivered, among which 97% were live infants and neo-
natal abnormalities were recorded in 9% of the cases
[12]. The rates of spontaneous abortions, miscarriages,
preterm deliveries, embryo-fetal anomalies and postnatal
neurological deterioration in children born to hyperpro-
lactinemic mothers receiving CAB have been found as
not being significantly different from those in normal
pregnancies [12,13].
M. Laloi-michelin et al. reported four cases of preg-
nant women who successfully received CAB therapy [6].
Two of these women had gastric intolerance with BRC
and tolerated CAB well. A third patient was under treat-
ment with Quinagolide and was switched to CAB due to
development of abnormal visual fields. The last case was
of a woman who developed persistent headache with
BRC treatment and her MRI showed an increase in
tumor size. She was switched to CAB in the eighth
month of pregnancy following which her tumor
regressed. It was suggested that CAB could be used as
an alternative treatment only when BRC failed. Similarly,
cases have been reported previously where CAB has
been employed for treatment of prolactinomas in situa-
tions where BRC therapy has failed [14-16]. It has been
deemed to be more effective and better tolerated than
BRC and has been associated with the birth of normal
full term infants.
We had initially switched our patient from BRC to
CAB because of intolerance to the former, following
which her Prolactin levels returned to normal limits and
she conceived. Weighing the benefits of continuation of
therapy during pregnancy against the risk of adverse
fetal outcomes, it was decided to prolong CAB treat-
ment throughout gestation at a lower dose. Literature
review had shown that the evidence of fetal abnormal-
ities and adverse pregnancy outcomes in such patients
was similar to that in the normal population. Moreover,
persistent therapy throughout pregnancy meant that the
size of the tumor could be condensed to an extent which
would later on enable us to withhold therapy after deliv-
ery to allow an innocuous period of six months for lacta-
tion. In addition, after delivery the effect of pregnancy
on growth of macroprolactinoma was no longer a threat,
the decision to stop CAB for lactation with a much
reduced tumor size was taken. With the exception of
cholestatic jaundice which occurred during the 28th
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week of gestation, the pregnancy was uneventful. Our
patient delivered a healthy baby at term.
Conclusion
To conclude, CAB was used safely and effectively to
treat macroprolactinoma during pregnancy in our case.
However, it is important to discuss with patients about
the limited data available on the use of CAB during
pregnancy and associated potential adverse effects on
the fetus.
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
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